2024-01-25 Protein FF meeting note

Participants

  • @Chapin Cavender

  • @Alexandra McIsaac

  • @Michael Gilson

  • @David Mobley

  • @Jeffrey Wagner

  • @Anika Friedman

  • @Brent Westbrook (Unlicensed)

  • @Trevor Gokey

  • @Pavan Behara

  • @Lily Wang

  • @Michael Shirts

Goals

  • Update on QM parameter fits

Recording

https://drive.google.com/file/d/1HZuD12lxwFXSdBZyPRYbUUNEzp0OIYF8/view?usp=sharing

Discussion topics

Item

Presenter

Notes

Item

Presenter

Notes

QM parameter fits

 

@Chapin Cavender

  • Slides go here

  • Issue with small molecules dominating objective--fixed by changing weights

    • MS--What parameters are iteration 0 starting from?

    • Null-0.0.2 is starting from Sage 2.0, others starting from MSM for valence terms, anything not covered by that gets Sage 2.1

    • MS – MSM valence terms are expected to be better than Sage 2.0? Or are they very different but not clearly better/worse?

    • CC – Brings more in line with small molecule fitting pipeline

    • CC--will look into basin depths as next step for benchmarking

  • DM--excited to see results

  • MS--grad student from UCSF reached out, very excited about Rosemary

LiveCOMS review discussion

 

  • CC – Re livecoms review - I’m just about done with my edits, then MG will look over those, then they’ll go out to coauthors.

  • MG – Issue of ShiftX vs. other methods - We’re going to write that up. Feel weird about including new results in a review paper.

    • MS – Yes, very interesting finding. And it’s a best practices paper, so it’s fine to include results.

    • MG – CC, could you email and ask for references on ShiftX being insufficient and the need for SPARTA+?

    • CC – Yes, will do

Nucleic acid project

 

  • DM – Also, it’s looking likely that we can attract industry money for NA+lipids. Moderna is likely to add money, OE may add person-time. We obviously can’t tell you to be involved in this but we think that you’d be very relevant and we’d appreciate your being as involved as you’re willing to be.

  •  

  •  

  •  

  •  

  •  

 

Action items

Decisions